These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 31795214)
21. Pinning down the polo-box domain. Lee KS; Idle JR Chem Biol; 2008 May; 15(5):415-6. PubMed ID: 18482691 [TBL] [Abstract][Full Text] [Related]
22. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy. Shakil S; Baig MH; Tabrez S; Rizvi SMD; Zaidi SK; Ashraf GM; Ansari SA; Khan AAP; Al-Qahtani MH; Abuzenadah AM; Chaudhary AG Semin Cancer Biol; 2019 Jun; 56():47-55. PubMed ID: 29122685 [TBL] [Abstract][Full Text] [Related]
23. A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay. Lu J; Xin S; Meng H; Veldman M; Schoenfeld D; Che C; Yan R; Zhong H; Li S; Lin S PLoS One; 2013; 8(4):e53317. PubMed ID: 23658603 [TBL] [Abstract][Full Text] [Related]
24. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919 [TBL] [Abstract][Full Text] [Related]
25. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1. Berg A; Berg T Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918 [TBL] [Abstract][Full Text] [Related]
26. Development of a Polo-like Kinase-1 Polo-Box Domain Inhibitor as a Tumor Growth Suppressor in Mice Models. Gunasekaran P; Yim MS; Ahn M; Soung NK; Park JE; Kim J; Bang G; Shin SC; Choi J; Kim M; Kim HN; Lee YH; Chung YH; Lee K; EunKyeong Kim E; Jeon YH; Kim MJ; Lee KR; Kim BY; Lee KS; Ryu EK; Bang JK J Med Chem; 2020 Dec; 63(23):14905-14920. PubMed ID: 33142063 [TBL] [Abstract][Full Text] [Related]
27. Structural insights into the inhibitor binding and new inhibitor design to Polo-like kinase-1 Polo-box domain using computational studies. Abdullah M; Guruprasad L J Biomol Struct Dyn; 2019 Aug; 37(13):3410-3421. PubMed ID: 30146942 [TBL] [Abstract][Full Text] [Related]
28. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity. Murugan RN; Park JE; Kim EH; Shin SY; Cheong C; Lee KS; Bang JK Mol Cells; 2011 Sep; 32(3):209-20. PubMed ID: 21809214 [TBL] [Abstract][Full Text] [Related]
29. Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators. Archambault V; Normandin K Cell Cycle; 2017 Jun; 16(12):1220-1224. PubMed ID: 28521657 [TBL] [Abstract][Full Text] [Related]
30. Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay. Normandin K; Lavallée JF; Futter M; Beautrait A; Duchaine J; Guiral S; Marinier A; Archambault V Sci Rep; 2016 Nov; 5():37581. PubMed ID: 27874094 [TBL] [Abstract][Full Text] [Related]
31. Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1. Kim SM; Chae MK; Lee C; Yim MS; Bang JK; Ryu EK Amino Acids; 2014 Nov; 46(11):2595-603. PubMed ID: 25151148 [TBL] [Abstract][Full Text] [Related]
32. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain. Park JE; Kim TS; Kim BY; Lee KS Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691 [TBL] [Abstract][Full Text] [Related]
33. Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells. Qin T; Chen F; Zhuo X; Guo X; Yun T; Liu Y; Zhang C; Lai L J Med Chem; 2016 Aug; 59(15):7089-96. PubMed ID: 27425654 [TBL] [Abstract][Full Text] [Related]
34. Ligand-based pharmacophore modeling, atom-based 3D-QSAR and molecular docking studies on substituted thiazoles and thiophenes as polo-like kinase 1 (Plk1) inhibitors. Chekkara R; Gorla VR; Susithra E; Tenkayala SR Comb Chem High Throughput Screen; 2014; 17(10):848-58. PubMed ID: 25346190 [TBL] [Abstract][Full Text] [Related]
35. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain. Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982 [TBL] [Abstract][Full Text] [Related]
36. Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds. Raab M; Sanhaji M; Pietsch L; Béquignon I; Herbrand AK; Süß E; Gande SL; Caspar B; Kudlinzki D; Saxena K; Sreeramulu S; Schwalbe H; Strebhardt K; Biondi RM ACS Chem Biol; 2018 Aug; 13(8):1921-1931. PubMed ID: 29927572 [TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy. Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948 [TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors. Lin TY; Min HP; Jiang C; Niu MM; Yan F; Xu LL; Di B Bioorg Med Chem; 2018 Jul; 26(12):3429-3437. PubMed ID: 29807699 [TBL] [Abstract][Full Text] [Related]
40. Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor. Baxter M; Chapagai D; Craig S; Hurtado C; Varghese J; Nurmemmedov E; Wyatt MD; McInnes C ChemMedChem; 2020 Jun; 15(12):1058-1066. PubMed ID: 32232973 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]